Patient characteristics and disposition
| Baseline characteristics | All patients | Patients with complete follow-up data |
|---|---|---|
| No in group | 147 | 110 |
| Age, years | 57.5 (14.2) | 57.9 (13.9) |
| Female sex, % (n) | 61.2 (90) | 61.0 (67) |
| Symptom duration, months | 5.7 (3.0) | 5.7 (2.9) |
| RF-positive | 71.7% (104) | 70.4% (76) |
| ACPA-positive | 63.8% (88) | 62.1% (64) |
| DAS28 | 5.23 (0.94) | 5.23 (0.88) |
| SJC (28) | 9.9 (5.1) | 10.4 (5.1) |
| TJC (28) | 7.1 (5.0) | 6.9 (4.7) |
| HAQ | 0.98 (0.51) | 1.00 (0.51) |
| ESR | 34.2 (24.6) | 34.0 (25.7) |
| Concurrent glucocorticoids | 17.7% (26) | 15.5% (17) |
| Total SvdH score | 3.78 (7.72) | 3.92 (8.23) |
Parenthesis: either SD or number of patients.
ACPA, anti-citrullinated protein antibodies; DAS28, 28 joint-based disease activity score; ESR, erythrocyte sedimentation rate; HAQ, health assessment questionnaire disability index; RF, rheumatoid factor; SJC, swollen joint count; SvdH, van der Heijde modified Sharp; TJC, tender joint count.